About Paul Lerou, MD

Lerou received his medical degree from Jefferson Medical School and completed his residency and chief residency in Pediatrics at Boston Children's Hospital, followed by a clinical fellowship in the Harvard Neonatal-Perinatal Medicine Fellowship Program.

He completed postdoctoral training in the George Daley Laboratory at Boston Children's Hospital, during which time he studied stem cell biology. Lerou's research is focused on using stem cells to better understand how genetic disorders and prematurity affect a child's development over the course of his or her lifetime and to ultimately develop new treatment strategies.  Currently his lab is using tracheal aspirate-derived lung progenitor cells to study bronchopulmonary dyplasia, a chronic lung disease that is one of the most common complications of premature birth.

Lerou joined MGHfC in October 1, 2015. Prior to that he was on faculty at Brigham & Women's Hospital NICU for 10 years, where he also served as medical director from 2014-2015.

Clinical Interests:




Neonatology and Newborn Medicine Unit
55 Fruit Street
Boston, MA 02114-2696
Phone: 617-724-9040
Fax: 617-726-9346

Medical Education

  • MD, Jefferson Medical College
  • MD, Sidney Kimmel Medical College at Thomas Jefferson University
  • Residency, Boston Children's Hospital
  • Residency, Children's Hospital of Boston
  • Fellowship, Boston Children's Hospital
  • Fellowship, Children's Hospital of Boston

American Board Certifications

  • Neonatal Perinatal Medicine, American Board of Pediatrics
  • Pediatrics, American Board of Pediatrics
  • Neonatal Perinatal Medicine, American Board of Pediatrics

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


Dr. Lerou studies bronchopulmonary dysplasia (BPD), a chronic lung disease that is one of the most common complications of extreme prematurity. Clinical interventions to prevent and treat BPD are complex and expensive, yet not very effective—the incidence of this disorder is unchanged over the past several decades. Dr. Lerou’s group studies the role and function of mesenchymal and epithelial progenitor cells derived directly from tracheal secretions of intubated newborns across a spectrum of disease and developmental maturity. They integrate innovative single cell, bioengineering, and developmental biology techniques. Patient-specific lung progenitors will improve our understanding of BPD and in the future can be used in a precision medicine approach to prevent and treat this disease.